PMID- 37105134
OWN - NLM
STAT- MEDLINE
DCOM- 20230809
LR  - 20240412
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 184
IP  - 8
DP  - 2023
TI  - Evaluation of Safety, Efficacy, and Compliance of Intralymphatic Immunotherapy 
      for Allergic Rhinoconjunctivitis: A Systematic Review and Meta-Analysis.
PG  - 754-766
LID - 10.1159/000529025 [doi]
AB  - INTRODUCTION: Intralymphatic immunotherapy (ILIT) is an emerging type of allergen 
      immunotherapy with fewer injections and shorter course for allergic 
      rhinoconjunctivitis (ARC). The efficacy and safety have not been confirmed by 
      informative and powerful evidence yet. METHODS: A systematic review and 
      meta-analysis were conducted through electronic searching with PubMed, Web of 
      Science, Embase, Scopus, and China National Knowledge Infrastructure (CNKI). The 
      safety (incidence of adverse events [AEs]), compliance (percent of patients 
      completing treatment), and clinical efficacy of ILIT were evaluated. Clinical 
      efficacy could be assessed by improvement of subjective symptom and rescue 
      medication use or the nasal tolerance to specific allergen. This study is 
      registered with PROSPERO (CRD42022353562). RESULTS: 12 randomized controlled 
      trials (RCTs) comparing ILIT with placebo and 3 trials (2 RCTs and one 
      case-control study) comparing ILIT and SCIT were included in this review. 
      Totally, 582 patients diagnosed as AR or ARC were enrolled. Almost all the AEs 
      were mild-to-moderate reactions except 2 patients developed anaphylactic 
      reactions at the intralymphatic injection dose 5,000 SQ-U in one study. ILIT got 
      higher incidence of local AEs than placebo, but their incidence of systemic AEs 
      was similar. ILIT was safer than SCIT (p < 0.05). Almost all the patients 
      could complete ILIT treatment, and the most common reason for discontinuation of 
      ILIT was AEs. The compliance of patients receiving ILIT seemed higher than 
      patients receiving SCIT. ILIT could significantly ameliorate subjective allergic 
      symptoms, especially for seasonal ARC, and increase nasal tolerance, similar to 
      SCIT. CONCLUSION: ILIT was a safe and effective treatment for ARC and could 
      achieve comparable clinical improvement with SCIT with shorter duration and 
      higher compliance. Moreover, ILIT was safer than SCIT.
CI  - (c) 2023 S. Karger AG, Basel.
FAU - Wang, Wenping
AU  - Wang W
AD  - Department of Allergy, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing, China, jenniferts@hsc.pku.edu.cn.
FAU - Wang, Xiaoyan
AU  - Wang X
AD  - Department of Allergy, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing, China.
FAU - Wang, Hongtian
AU  - Wang H
AD  - Department of Allergy, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing, China.
FAU - Wang, Xueyan
AU  - Wang X
AD  - Department of Allergy, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing, China.
AD  - Center of Allergy, Capital Medical University Affiliated Beijing Shijitan 
      Hospital, Beijing, China.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230427
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Allergens)
SB  - IM
MH  - Humans
MH  - *Allergens
MH  - Desensitization, Immunologic/adverse effects
MH  - Immunotherapy
MH  - Treatment Outcome
MH  - Injections, Intralymphatic
MH  - *Anaphylaxis/etiology
MH  - Injections, Subcutaneous
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Allergic rhinoconjunctivitis
OT  - Intralymphatic immunotherapy
OT  - Meta-analysis
OT  - Subcutaneous immunotherapy
EDAT- 2023/04/28 00:42
MHDA- 2023/08/09 06:43
CRDT- 2023/04/27 18:22
PHST- 2022/07/24 00:00 [received]
PHST- 2022/12/13 00:00 [accepted]
PHST- 2023/08/09 06:43 [medline]
PHST- 2023/04/28 00:42 [pubmed]
PHST- 2023/04/27 18:22 [entrez]
AID - 000529025 [pii]
AID - 10.1159/000529025 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2023;184(8):754-766. doi: 10.1159/000529025. Epub 2023 
      Apr 27.